<DOC>
	<DOCNO>NCT01436045</DOCNO>
	<brief_summary>The purpose study investigate effect rapidly act intranasal insulin derivative ( glulisine ) memory cognition 12 patient suffer mild-moderate Alzheimer 's Disease ( AD ) use double-blind placebo-controlled single dose study . This study ass safety insulin glulisine well effect drug olfaction .</brief_summary>
	<brief_title>Safety Effectiveness Study Intranasal Insulin Glulisine Cognitive Memory Mild-Mod AD Patients .</brief_title>
	<detailed_description>A single center , phase II randomize , double-blind , placebo-controlled , cross-over study design ass efficacy safety intranasally ( IN ) deliver insulin glulisine versus placebo patient age 65-85 mild-moderate Alzheimer 's Disease ( AD ) . Twelve AD subject ( six female six male ) randomize receive single dose either 20 IU/IN insulin glulisine placebo use MAD 300 device .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female subject clinical diagnosis probable AD accordance National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria Dementia Rating Scale ( McKhann 1984 ) . MiniMental State Examination ( MMSE ) score 1826 . Hachinski Ischemia Score &lt; 4 . Age &gt; 65 &lt; 85 year Females must &gt; 2 year postmenopausal surgically sterile . Must able speak , read understand English order comply test cognitive function , memory physiology . Must dedicate family member /caregiver , able attend visit report subject 's status . Subject family member/caregiver provide fully inform write consent prior participation . In event subject legally unable provide inform write consent due deterioration cognitive ability , fully inform write consent must provide legally authorize representative . On stable dose ( â‰¥ 1 month ) prescribe acetylcholinesterase inhibitor ( e.g . donepezil , rivastigmine , galantamine ) and/or memantine . A brain CT MRI last 2 year compatible diagnosis probable Alzheimer 's Disease . A Clinical Dementia Rating ( CDR ) range 1 2 . Medical history and/or clinically determine evidence central nervous system ( CNS ) disorder include brain tumor , active subdural hematoma , seizure disorder , multiple sclerosis dementia Lewy body , vascular dementia , corticobasal syndrome , progressive supranuclear palsy , Parkinson 's disease , multiple system atrophy , frontotemporal dementia , normal pressure hydrocephalus , Huntington 's disease , JakobCreutzfeldt disease present dementia . Personal medical history and/or clinically determine disorder : current B12 deficiency , positive syphilis serology , chronic sinusitis untreated thyroid disease , significant head trauma , history difficulty smell and/or taste prior AD diagnosis . Diagnosis form diabetes mellitus , actively take insulin , HbA1c &gt; 6.1 % screening . Personal history follow : moderate severe pulmonary disease , congestive heart failure , significant cardiovascular and/or cerebrovascular event previous 6 month , condition know affect absorption , distribution , metabolism , excretion drug hepatic , renal gastrointestinal disease clinically relevant abnormality inclusion would pose safety risk subject determine Investigator . Heavy smoker ( define smoke half pack per day last 10 year prior entry study ) . Personal history psychiatric illness , except major depressive disorder ( accord Diagnostic Statistical Manual ( DSM ) IV TR ) currently remission stable treatment &gt; 2 year , psychiatric condition inclusion would pose safety risk subject determine Investigator . Patients active depression ( Geriatric Depression Score &gt; 9 ) exclude study . Currently take medication , herbal food supplement determine Investigator interfere procedural test cognitive function well ensure study safety . Recent change ( &lt; 1 month ) prescribe acetylcholinesterase inhibitor ( e.g . donepezil , rivastigmine , galantamine ) memantine . Current recent drug alcohol abuse dependence define DSMIV TR . Systolic blood pressure &gt; 160 &lt; 90 mmHg diastolic blood pressure &gt; 100 &lt; 60 mmHg Screening . Screening laboratory result medically relevant would pose safety risk subject determine Investigator . Participation research study least 3 month prior study . Insulin allergy . History significant traumatic brain injury History acute chronic rhinitis and/or sinusitis . Legally unable provide inform write consent due deterioration cognitive ability .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Memory</keyword>
	<keyword>Insulin glulisine</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>